The Applications and Prospects of Blockade of Programmed Death—1 Antibody in the Process of Treating Colorectal Cancer

Abstract

Nowadays, malignancies has become the second killer in the world. In America, the colorectal cancer is the second major cancer among all kinds of malignancies. Recently, the antibody, PD-1 has been applied to several types of cancers, like lung cancer, cancer of liver, and melanoma etc., so has colorectal cancer. According to clinical researches, the PD-1 antibody therapy has distinctive effects on the MMR(mismatch repair) deficient colorectal cancer, neither does the non-MMR deficient colorectal carcinoma. In addition, the mechanizations of the process using PD-1 antibody to cure the MMR deficient colorectal cancer are still unknown. In this article, we summarize the evolutions and present situations of the researches about PD-1 antibody which involves in the cure for colorectal cancer and discuss the principles of it. Apart from that, the possibilities that PD-1 antibody will be applied to the treatment of non-MMR deficient colorectal cancer are also forecasted.